Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain

Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet